Key facts
- Vivan Therapeutics’s last known valuation is $17.6M (Dec 2024).
- It has raised $6.0M; the latest was Accelerator/Incubator in Jul 2025.
- Notable investors include Innovate UK, European Innovation Council, SFC Capital, National Institutes of Health, London & Partners. — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Vivan Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vivan Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vivan Therapeutics
Developer of personalized therapeutics designed to transform cancer care. The company's technology follows the personal discovery process (PDP), a massive clinical trial for a single patient, where the genetic complexity of each patient's tumor network is engineered into a group of fruit flies and robotics are used to evaluate FDA-approved drugs including non-cancer drugs, enabling cancer patients with better treatment recommendations and developing new diagnostics and decision support tools to make cancer treatment more effective.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2018
- Employees
- 23
- Website
- vivantx.com/
- Ownership
- Privately Held (backing)
Vivan Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vivan Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vivan Therapeutics in its N-PORT filings yet. We sweep new filings monthly.